# Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer

> **NCT02588105** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 84 (actual)

## Conditions studied

- Advanced Solid Tumours

## Interventions

- **DRUG:** AZD0156
- **DRUG:** Olaparib
- **DRUG:** irinotecan
- **DRUG:** Fluorouracil
- **DRUG:** Folinic Acid

## Key facts

- **NCT ID:** NCT02588105
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-10
- **Primary completion:** 2019-09-13
- **Final completion:** 2022-07-26
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2022-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02588105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02588105, "Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02588105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*